Buy
Took a position
After all these years. Happy to see Jennifer and others booted out, don't mind the dilution, was probably necessary, but the compensations they paid to themselves for babysitting a tortoise when shareholders bled was unconscionable.
With this capital infusion from Rosalind and an uplifting to Nasdaq see a runup to $25 in the horizon. CLSN, long trading along with DCTH, is not valued at 145 million in cap, so Delcath's 30 million has room to run here.
Hello to all the old-timers.